Vilazodone
- TRADE NAME: Viibryd (Merck KGaA)
- INDICATIONS: Major depressive disorder
- CLASS: Antidepressant, Serotonin-norepinephrine reuptake inhibitor
- HALF-LIFE: 25 hours
FDA APPROVAL DATE: 01/21/2011
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Anticoagulants, Aspirin, Buspirone, CNS-active agents, CYP3A4 inhibitors or inducers, Efavirenz, Erythromycin, Ketoconazole, MAO inhibitors, NSAIDs, SNRIs, SSRIs, Tramadol, Triptans, Tryptophan, Warfarin
PREGNANCY CATEGORY: C
SUICIDALITY AND ANTIDEPRESSANT DRUGS
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
NEUROMUSCULAR/SKELETAL.
OCULAR.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric